Breaking boundaries—coagulation and fibrinolysis at the neurovascular interface

Frontiers in Cellular Neuroscience

Volumn 9, Issue September, 2015, Pages

  Bardehie, Sophia ^a   Rafalski, Victoria A ^a   Akassoglou, Katerina ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer s disease; Autoimmunity; Blood brain barrier; Fibrinogen; Microglia; Multiple sclerosis; Neurodegeneration; Neuroinflammation

Indexed keywords

FIBRIN; PLASMINOGEN;

BLOOD BRAIN BARRIER; BLOOD CLOTTING; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FIBRIN DEPOSITION; FIBRINOLYSIS; HUMAN; IMMUNE RESPONSE; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

EID: 84942929066     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2015.00354     Document Type: Review

References (110)

1. Abu Fanne, R., Nassar, T., Yarovoi, S., Rayan, A., Lamensdorf, I., Karakoveski, M., et al. (2010). Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology 58, 972-980. doi: 10.1016/j.neuropharm.2009.12.017
2. Adams, R. A., Bauer, J., Flick, M. J., Sikorski, S. L., Nuriel, T., Lassmann, H., et al. (2007). The fibrin-derived gamma377-395 peptide inhibits microglia activation and suppresses relapsing paralysis in central nervous system autoimmune disease. J. Exp. Med. 204, 571-582. doi: 10.1084/jem.20061931
3. Adams, R. A., Passino, M., Sachs, B. D., Nuriel, T., and Akassoglou, K. (2004). Fibrin mechanisms and functions in nervous system pathology. Mol. Interv. 4, 163-176. doi: 10.1124/mi.4.3.6
4. Ahn, H. J., Glickman, J. F., Poon, K. L., Zamolodchikov, D., Jno-Charles, O. C., Norris, E. H., et al. (2014). A novel Abeta-fibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer’s disease mice. J. Exp. Med. 211, 1049-1062. doi: 10.1084/jem.20131751
5. Ahn, H. J., Zamolodchikov, D., Cortes-Canteli, M., Norris, E. H., Glickman, J. F., and Strickland, S. (2010). Alzheimer’s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization. Proc. Natl. Acad. Sci. USA 107,21812-21817. doi: 10.1073/pnas.1010373107
6. Akassoglou, K. (2015). Coagulation takes center stage in inflammation. Blood 125, 419-420. doi: 10.1182/blood-2014-11-609222
7. Akassoglou, K., Adams, R. A., Bauer, J., Mercado, P., Tseveleki, V., Lassmann, H., et al. (2004). Fibrin depletion decreases inflammation and delays the onset of demyelination in a tumor necrosis factor transgenic mouse model for multiple sclerosis. Proc. Natl. Acad. Sci. USA 101, 6698-6703. doi: 10.1073/pnas.0303859101
8. Akassoglou, K., Akpinar, P., Murray, S., and Strickland, S. (2003). Fibrin is a regulator of schwann cell migration after sciatic nerve injury in mice. Neurosci. Lett. 338, 185-188. doi: 10.1016/s0304-3940(02)01387-3
9. Akassoglou, K., Kombrinck, K. W., Degen, J. L., and Strickland, S. (2000). Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury. J. Cell Biol. 149, 1157-1166. doi: 10.1083/jcb.149.5.1157
10. Akassoglou, K., Yu, W. M., Akpinar, P., and Strickland, S. (2002). Fibrin inhibits peripheral nerve remyelination by regulating schwann cell differentiation. Neuron 33, 861-875. doi: 10.1016/s0896-6273(02)00617-7
11. Aksungar, F. B., Topkaya, A. E., Yildiz, Z., Sahin, S., and Turk, U. (2008). Coagulation status and biochemical and inflammatory markers in multiple sclerosis. J. Clin. Neurosci. 15, 393-397. doi: 10.1016/j.jocn.2007.02.090
12. Alabanza, L. M., and Bynoe, M. S. (2012). Thrombin induces an inflammatory phenotype in a human brain endothelial cell line. J. Neuroimmunol. 245, 48-55. doi: 10.1016/j.jneuroim.2012.02.004
13. Belayev, L., Busto, R., Zhao, W., and Ginsberg, M. D. (1996). Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 739, 88-96. doi: 10.1016/s0006-8993(96)00815-3
14. Bignami, A., Cella, G., and Chi, N. H. (1982). Plasminogen activators in rat neural tissues during development and in wallerian degeneration. Acta Neuropathol. 58, 224-228. doi: 10.1007/bf00690805
15. Bugge, T. H., Flick, M. J., Daugherty, C. C., and Degen, J. L. (1995). Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev. 9, 794-807. doi: 10.1101/gad.9.7.794
16. Bugge, T. H., Kombrinck, K. W., Flick, M. J., Daugherty, C. C., Danton, M. J., and Degen, J. L. (1996). Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87, 709-719. doi: 10.1016/s0092-8674(00)81390-2
17. Carroll, P. M., Tsirka, S. E., Richards, W. G., Frohman, M. A., and Strickland, S. (1994). The mouse tissue plasminogen activator gene 5’ flankingregion directs appropriate expression in development and a seizure-enhanced response in the CNS. Development 120, 3173-3183.
18. Castellino, F. J., and Ploplis, V. A. (2005). Structure and function of the plasminogen/plasmin system. Thromb. Haemost. 93, 647-654. doi: 10.1160/th04-12-0842
19. Cesarman-Maus, G., and Hajjar, K. A. (2005). Molecular mechanisms of fibrinolysis. Br. J. Haematol. 129, 307-321. doi: 10.1111/j.1365-2141.2005.05444.x
20. Chen, B., Friedman, B., Whitney, M. A., Winkle, J. A., Lei, I. F., Olson, E. S., et al. (2012). Thrombin activity associated with neuronal damage during acute focal ischemia. J. Neurosci. 32, 7622-7631. doi: 10.1523/jneurosci.0369-12.2012
21. Conti, A., Sanchez-Ruiz, Y., Bachi, A., Beretta, L., Grandi, E., Beltramo, M., et al. (2004). Proteome study of human cerebrospinal fluid following traumatic brain injury indicates fibrin(ogen) degradation products as trauma-associated markers. J. Neurotrauma 21, 854-863. doi: 10.1089/0897715041526212
22. Cortes-Canteli, M., Mattei, L., Richards, A. T., Norris, E. H., and Strickland, S. (2015). Fibrin deposited in the Alzheimer’s disease brain promotes neuronal degeneration. Neurobiol. Aging 36, 608-617. doi: 10.1016/j.neurobiolaging.2014.10.030
23. Cortes-Canteli, M., Paul, J., Norris, E. H., Bronstein, R., Ahn, H. J., Zamolodchikov, D., et al. (2010). Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer’s disease. Neuron 66, 695-709. doi: 10.1016/j.neuron.2010.05.014
24. Craig-Schapiro, R., Kuhn, M., Xiong, C., Pickering, E. H., Liu, J., Misko, T. P., et al. (2011). Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer’s disease diagnosis and prognosis. PLoS One 6:e18850. doi: 10.1371/journal.pone.0018850
25. Cristante, E., McArthur, S., Mauro, C., Maggioli, E., Romero, I. A., Wylezinska- Arridge, M., et al. (2013). Identification of an essential endogenous regulator of blood-brain barrier integrity and its pathological and therapeutic implications. Proc. Natl. Acad. Sci. USA 110,832-841. doi: 10.1073/pnas.1209362110
26. Cullen, K. M., Kócsi, Z., and Stone, J. (2006). Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol. Aging27, 1786-1796. doi: 10.1016/j.neurobiolaging.2005.10.016
27. Cuzner, M. L., and Opdenakker, G. (1999). Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system. J. Neuroimmunol. 94, 1-14. doi: 10.1016/s0165-5728(98)00241-0
28. Dallasta, L. M., Pisarov, L. A., Esplen, J. E., Werley, J. V., Moses, A. V., Nelson, J. A., et al. (1999). Blood-brain barrier tight junction disruption in human immunodeficiencyvirus-1 encephalitis. Am. J. Pathol. 155, 1915-1927. doi: 10.1016/s0002-9440(10)65511-3
29. Daneman, R., and Prat, A. (2015). The blood-brain barrier. Cold Spring Harb. Perspect. Biol. 7:a020412. doi: 10.1101/cshperspect.a020412
30. Davalos, D., and Akassoglou, K. (2012). Fibrinogen as a key regulator of inflammation in disease. Semin. Immunopathol. 34, 43-62. doi: 10.1007/s00281-011-0290-8
31. Davalos, D., Baeten, K. M., Whitney, M. A., Mullins, E. S., Friedman, B., Olson, E. S., et al. (2014). Early detection of thrombin activity in neuroinflammatory disease. Ann. Neurol. 75, 303-308. doi: 10.1002/ana.24078
32. Davalos, D., Ryu, J. K., Merlini, M., Baeten, K. M., Le Moan, N., Petersen, M. A., et al. (2012). Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat. Commun. 3:1227. doi: 10.1038/ncomms2230
33. Dohgu, S., Takata, F., Matsumoto, J., Oda, M., Harada, E., Watanabe, T., et al. (2011). Autocrine and paracrine up-regulation of blood-brain barrier function by plasminogen activator inhibitor-1. Microvasc. Res. 81, 103-107. doi: 10.1016/j.mvr.2010.10.004
34. East, E., Baker, D., Pryce, G., Lijnen, H. R., Cuzner, M. L., and Gveric, D. (2005). A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitis. Am. J. Pathol. 167, 545-554. doi: 10.1016/s0002-9440(10)62996-3
35. East, E., Gveric, D., Baker, D., Pryce, G., Lijnen, H. R., and Cuzner, M. L. (2008). Chronic relapsing experimental allergic encephalomyelitis (CREAE) in plasminogen activator inhibitor-1 knockout mice: the effect of fibrinolysis duringneuroinflammation. Neuropathol. Appl. Neurobiol. 34,216-230. doi: 10.1111/j.1365-2990.2007.00889.x
36. Elster, A. D., and Moody, D. M. (1990). Early cerebral infarction: gadopentetate dimeglumine enhancement. Radiology 177, 627-632. doi: 10.1148/radiology.177.3.2243961
37. Fugate, J. E., and Rabinstein, A. A. (2014). Update on intravenous recombinant tissue plasminogen activator for acute ischemic stroke. Mayo Clin. Proc. 89, 960-972. doi: 10.1016/j.mayocp.2014.03.001
38. Gaitán, M. I., Shea, C. D., Evangelou, I. E., Stone, R. D., Fenton, K. M., Bielekova, B., et al. (2011). Evolution ofthe blood-brain barrier in newlyforming multiple sclerosis lesions. Ann. Neurol. 70, 22-29. doi: 10.1002/ana.22472
39. Gay, D., and Esiri, M. (1991). Blood-brain barrier damage in acute multiple sclerosis plaques. An immunocytological study. Brain 114, 557-572. doi: 10.1093/brain/114.1.557
40. Grossman, R. I., Braffman, B. H., Brorson, J. R., Goldberg, H. I., Silberberg, D. H., and Gonzalez-Scarano, F. (1988). Multiple sclerosis: serial studyofgadolinium-enhanced MR imaging. Radiology 169, 117-122. doi: 10.1148/radiology.169.1.3420246
41. Gveric, D., Herrera, B., Petzold, A., Lawrence, D. A., and Cuzner, M. L. (2003). Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 126, 1590-1598. doi: 10.1093/brain/awg167
42. Han, M. H., Hwang, S. I., Roy, D. B., Lundgren, D. H., Price, J. V., Ousman, S. S., et al. (2008). Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451, 1076-1081. doi: 10.1038/nature06559
43. Huang, Y., and Mucke, L. (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148, 1204-1222. doi: 10.1016/j.cell.2012.02.040
44. Hultman, K., Cortes-Canteli, M., Bounoutas, A., Richards, A. T., Strickland, S., and Norris, E. H. (2014). Plasmin deficiencyleads to fibrin accumulation and a compromised inflammatoryresponse in the mouse brain. J. Thromb. Haemost. 12,701-712. doi: 10.1111/jth.12553
45. Hultman, K., Strickland, S., and Norris, E. H. (2013). The APOE varepsilon4/varepsilon4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains ofAlzheimer’s disease patients. J. Cereb. Blood Flow Metab. 33, 1251-1258. doi: 10.1038/jcbfm.2013.76
46. Ill-Raga, G., Palomer, E., Ramos-Fernández, E., Guix, F. X., Bosch-Morató, M., Guivernau, B., et al. (2015). Fibrinogen nitrotyrosination after ischemic stroke impairs thrombolysis and promotes neuronal death. Biochim. Biophys. Acta 1852,421-428. doi: 10.1016/j.bbadis.2014.12.007
47. Jennewein, C., Tran, N., Paulus, P., Ellinghaus, P., Eble, J. A., and Zacharowski, K. (2011). Novel aspects of fibrin(ogen) fragments during inflammation. Mol. Med. 17, 568-573. doi: 10.2119/molmed.2010.00146
48. Kaczmarek, E., Lee, M. H., and McDonagh, J. (1993). Initial interaction between fibrin and tissue plasminogen activator (t-PA). The Gly-Pro-Arg-Pro binding site on fibrin(ogen) is important for t-PA activity. J. Biol. Chem. 268, 2474-2479.
49. Kaur, J., Tuor, U. I., Zhao, Z., and Barber, P. A. (2011). Quantitative MRI reveals the elderly ischemic brain is susceptible to increased early blood-brain barrier permeability following tissue plasminogen activator related to claudin 5 and occludin disassembly. J. Cereb. Blood Flow Metab. 31, 1874-1885. doi: 10.1038/jcbfm.2011.79
50. Kim, P. Y., Tieu, L. D., Stafford, A. R., Fredenburgh, J. C., and Weitz, J. I. (2012). A high affinity interaction of plasminogen with fibrin is not essential for efficient activation bytissue-type plasminogen activator. J. Biol. Chem. 287, 4652-4661. doi: 10.1074/jbc.m111.317719
51. Kirk, J., Plumb, J., Mirakhur, M., and McQuaid, S. (2003). Tight junctional abnormality in multiple sclerosis white matter affects all calibres of vessel and is associated with blood-brain barrier leakage and active demyelination. J. Pathol. 201, 319-327. doi: 10.1002/path.1434
52. Korschenhausen, D. A., Hampel, H. J., Ackenheil, M., Penning, R., and Muller, N. (1996). Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr. Res. 19, 103-109. doi: 10.1016/0920-9964(95)00073-9
53. Kwaan, H. C. (2014). From fibrinolysis to the plasminogen-plasmin system and beyond: a remarkable growth of knowledge, with personal observations on the history of fibrinolysis. Semin. Thromb. Hemost. 40, 585-591. doi: 10.1055/s-0034-1383545
54. Lakhan, S. E., Kirchgessner, A., Tepper, D., and Leonard, A. (2013). Matrix metalloproteinases and blood-brain barrier disruption in acute ischemic stroke. Front. Neurol. 4:32. doi: 10.3389/fneur.2013.00032
55. Lee, K. R., Kawai, N., Kim, S., Sagher, O., and Hoff, J. T. (1997). Mechanisms of edema formation after intracerebral hemorrhage: effects of thrombin on cerebral blood flow, blood-brain barrier permeability and cell survival in a rat model. J. Neurosurg. 86, 272-278. doi: 10.3171/jns.1997.86.2.0272
56. Liguori, M., Qualtieri, A., Tortorella, C., Direnzo, V., Bagala, A., Mastrapasqua, M., et al. (2014). Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration. PLoS One 9:e103984. doi: 10.1371/journal.pone.0103984
57. Liu, D. Z., Ander, B. P., Xu, H., Shen, Y., Kaur, P., Deng, W., et al. (2010). Blood- brain barrier breakdown and repair by Src after thrombin-induced injury. Ann. Neurol. 67, 526-533. doi: 10.1002/ana.21924
58. Liu, J. Y., Thom, M., Catarino, C. B., Martinian, L., Figarella-Branger, D., Bartolomei, F., et al. (2012). Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 135, 3115-3133. doi: 10.1093/brain/aws147
59. Lu, W., Bhasin, M., and Tsirka, S. E. (2002). Involvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitis. J. Neurosci. 22, 10781-10789.
60. Mahley, R. W., and Huang, Y. (2012). Apolipoprotein e sets the stage: response to injury triggers neuropathology. Neuron 76, 871-885. doi: 10.1016/j.neuron.2012.11.020
61. Marik, C., Felts, P. A., Bauer, J., Lassmann, H., and Smith, K. J. (2007). Lesion genesis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain 130,2800-2815. doi: 10.1093/brain/awm236
62. Massberg, S., Enders, G., Matos, F. C., Tomic, L. I., Leiderer, R., Eisenmenger, S., et al. (1999). Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood 94, 3829-3838.
63. Melchor, J. P., Pawlak, R., and Strickland, S. (2003). The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J. Neurosci. 23, 8867-8871.
64. Melchor, J. P., and Strickland, S. (2005). Tissue plasminogen activator in central nervous system physiology and pathology. Thromb. Haemost. 93, 655-660. doi: 10.1160/th04-12-0838
65. Miller, D. H., Rudge, P., Johnson, G., Kendall, B. E., Macmanus, D. G., Moseley, I. F., et al. (1988). Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain 111, 927-939. doi: 10.1093/brain/111.4.927
66. Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., et al. (2015). Blood-brain barrier breakdown in the aging human hippocampus. Neuron 85, 296-302. doi: 10.1016/j.neuron.2014.12.032
67. Morrow, D. A., Braunwald, E., Bonaca, M. P., Ameriso, S. F., Dalby, A. J., Fish, M. P., et al. (2012). Vorapaxar in the secondary prevention of atherothrombotic events. N. Engl. J. Med. 366, 1404-1413. doi: 10.1056/NEJMoa1200933
68. Muradashvili, N., Tyagi, N., Tyagi, R., Munjal, C., and Lominadze, D. (2011). Fibrinogen alters mouse brain endothelial cell layer integrity affecting vascular endothelial cadherin. Biochem. Biophys. Res. Commun. 413, 509-514. doi: 10.1016/j.bbrc.2011.07.133
69. Niego, B., Freeman, R., Puschmann, T. B., Turnley, A. M., and Medcalf, R. L.(2011). t-PA-specific modulation of a human blood-brain barrier model involves plasmin-mediated activation of the Rho kinase pathway in astrocytes. Blood 119,4752-4761. doi: 10.1182/blood-2011-07-369512
70. Oh, S. B., Byun, C. J., Yun, J. H., Jo, D. G., Carmeliet, P., Koh, J. Y., et al. (2014a). Tissue plasminogen activator arrests Alzheimer’s disease pathogenesis. Neurobiol. Aging 35, 511-519. doi: 10.1016/j.neurobiolaging.2013.09.020
71. Oh, J., Lee, H. J., Song, J. H., Park, S. I., and Kim, H. (2014b). Plasminogen activator inhibitor-1 as an earlypotential diagnostic markerforAlzheimer’s disease. Exp. Gerontol. 60,87-91. doi: 10.1016/j.exger.2014.10.004
72. Paterson, P. Y. (1976). Experimental allergic encephalomyelitis: role of fibrin deposition in immunopathogenesis of inflammation in rats. Fed. Proc. 35, 2428-2434.
73. Paterson, P. Y., Koh, C. S., and Kwaan, H. C. (1987). Role of the clotting system in the pathogenesis of neuroimmunologic disease. Fed. Proc. 46, 91-96.
74. Patibandla, P. K., Tyagi, N., Dean, W. L., Tyagi, S. C., Roberts, A. M., and Lominadze, D. (2009). Fibrinogen induces alterations of endothelial cell tight junction proteins. J. Cell. Physiol. 221, 195-203. doi: 10.1002/jcp.21845
75. Paul, J., Strickland, S., and Melchor, J. P. (2007). Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer’s disease. J. Exp. Med. 204, 1999-2008. doi: 10.1084/jem.20070304
76. Qian, Z., Gilbert, M. E., Colicos, M. A., Kandel, E. R., and Kuhl, D. (1993). Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 361, 453-457. doi: 10.1038/361453a0
77. Rubel, C., Fernández, G. C., Dran, G., Bompadre, M. B., Isturiz, M. A., and Palermo, M. S. (2001). Fibrinogen promotes neutrophil activation and delays apoptosis. J. Immunol. 166, 2002-2010. doi: 10.4049/jimmunol.166.3.2002
78. Ryu, J. K., Davalos, D., and Akassoglou, K. (2009). Fibrinogen signal transduction in the nervous system. J. Thromb. Haemost. 7(Suppl. 1), 151-154. doi: 10.1111/j.1538-7836.2009.03438.x
79. Ryu, J. K., and McLarnon, J. G. (2009). A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain. J. Cell. Mol. Med. 13, 2911-2925. doi: 10.1111/j.1582-4934.2008.00434.x
80. Ryu, J. K., Petersen, M. A., Murray, S. G., Baeten, K. M., Meyer-Franke, A., Chan, J. P., et al. (2015). Blood coagulation protein fibrinogen promotes autoimmunity and demyelination via chemokine release and antigen presentation. Nat. Commun. 6:8164. doi: 10.1038/ncomms9164
81. Sappino, A. P., Madani, R., Huarte, J., Belin, D., Kiss, J. Z., Wohlwend, A., et al. (1993). Extracellular proteolysis in the adult murine brain. J. Clin. Invest. 92, 679-685. doi: 10.1172/jci116637
82. Schachtrup, C., Lu, P., Jones, L. L., Lee, J. K., Lu, J., Sachs, B. D., et al. (2007). Fibrinogen inhibits neurite outgrowth via beta3 integrin-mediated phosphorylation of the EGF receptor. Proc. Natl. Acad. Sci. USA 104, 11814-11819. doi: 10.1073/pnas.0704045104
83. Schachtrup, C., Ryu, J. K., Helmrick, M. J., Vagena, E., Galanakis, D. K., Degen, J. L., et al. (2010). Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF-beta after vascular damage. J. Neurosci. 30, 5843-5854. doi: 10.1523/JNEUROSCI.0137-10.2010
84. Shlosberg, D., Benifla, M., Kaufer, D., and Friedman, A. (2010). Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat. Rev. Neurol. 6, 393-403. doi: 10.1038/nrneurol.2010.74
85. Siconolfi, L. B., and Seeds, N. W. (2001). Mice lacking tPA, uPA, or plasminogen genes showed delayed functional recovery after sciatic nerve crush. J. Neurosci. 21,4348-4355.
86. Skogen, W. F., Senior, R. M., Griffin, G. L., and Wilner, G. D. (1988). Fibrinogen- derived peptide B beta 1-42 is a multidomained neutrophil chemoattractant. Blood 71, 1475-1479.
87. Skrzypiec, A. E., Maiya, R., Chen, Z., Pawlak, R., and Strickland, S. (2009). Plasmin- mediated degradation of laminin gamma-1 is critical for ethanol-induced neurodegeneration. Biol. Psychiatry 66, 785-794. doi: 10.1016/j.biopsych.2009.05.021
88. Smiley, S. T., King, J. A., and Hancock, W. W. (2001). Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J. Immunol. 167, 2887-2894. doi: 10.4049/jimmunol.167.5.2887
89. Sokrab, T. E., Kalimo, H., and Johansson, B. B. (1990). Parenchymal changes related to plasma protein extravasation in experimental seizures. Epilepsia 31, 1-8. doi: 10.1111/j.1528-1157.1990.tb05352.x
90. Stamatovic, S. M., Keep, R. F., and Andjelkovic, A. V. (2008). Brain endothelial cell-cell junctions: how to ‘‘open’’ the blood brain barrier. Curr. Neuropharmacol. 6, 179-192. doi: 10.2174/157015908785777210
91. Su, E. J., Fredriksson, L., Geyer, M., Folestad, E., Cale, J., Andrae, J., et al. (2007). Activation ofPDGF-CC by tissue plasminogen activator impairs blood- brain barrier integrity during ischemic stroke. Nat. Med. 14, 731-737. doi: 10.1038/nm1787
92. Syrovets, T., and Simmet, T. (2004). Novel aspects and new roles for the serine protease plasmin. Cell. Mol. Life Sci. 61, 873-885. doi: 10.1007/s00018-003-3348-5
93. Takada, Y., Ono, Y., Saegusa, J., Mitsiades, C., Mitsiades, N., Tsai, J., et al. (2010). A T cell-binding fragment of fibrinogen can prevent autoimmunity. J. Autoimmun. 34, 453-459. doi: 10.1016/j.jaut.2009.11.017
94. Tanno, H., Nockels, R. P., Pitts, L. H., and Noble, L. J. (1992). Breakdown of the blood-brain barrier after fluid percussive brain injury in the rat. Part 1: distribution and time course of protein extravasation. J. Neurotrauma 9, 21-32. doi: 10.1089/neu.1992.9.21
95. Tsirka, S. E., Gualandris, A., Amaral, D. G., and Strickland, S. (1995). Excitotoxin- induced neuronal degeneration and seizure are mediated bytissue plasminogen activator. Nature 377, 340-344. doi: 10.1038/377340a0
96. Tucsek, Z., Toth, P., Sosnowska, D., Gautam, T., Mitschelen, M., Koller, A., et al. (2014). Obesity in aging exacerbates blood-brain barrier disruption, neuroinflammation and oxidative stress in the mouse hippocampus: effects on expression of genes involved in beta-amyloid generation and Alzheimer’s disease. J. Gerontol. A Biol. Sci. Med. Sci. 69, 1212-1226. doi: 10.1093/gerona/glt177
97. Tyagi, N., Roberts, A. M., Dean, W. L., Tyagi, S. C., and Lominadze, D. (2008). Fibrinogen induces endothelial cell permeability. Mol. Cell. Biochem. 307, 13-22. doi: 10.1007/s11010-007-9579-2
98. van Oijen, M., Witteman, J. C., Hofman, A., Koudstaal, P. J., and Breteler, M. M. (2005). Fibrinogen is associated with an increased risk of alzheimer disease and vascular dementia. Stroke 36, 2637-2641. doi: 10.1161/01.str.0000189721.31432.26
99. Verbout, N. G., Yu, X., Healy, L. D., Phillips, K. G., Tucker, E. I., Gruber, A., et al. (2015). Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. Metab. Brain Dis. 30, 57-65. doi: 10.1007/s11011-014-9558-8
100. Viggars, A. P., Wharton, S. B., Simpson, J. E., Matthews, F. E., Brayne, C., Savva, G. M., et al. (2011). Alterations in the blood brain barrier in ageing cerebral cortex in relationship to alzheimer-type pathology: a study in the MRC-CFAS population neuropathology cohort. Neurosci. Lett. 505, 25-30. doi: 10.1016/j.neulet.2011.09.049
101. Vivien, D., Gauberti, M., Montagne, A., Defer, G., and Touzé, E. (2011). Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence. J. Cereb. Blood Flow Metab. 31, 2119-2134. doi: 10.1038/jcbfm.2011.127
102. Vos, C. M., Geurts, J. J., Montagne, L., van Haastert, E. S., Bo, L., van der Valk, P., et al. (2005). Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. Neurobiol. Dis. 20, 953-960. doi: 10.1016/j.nbd.2005.06.012
103. Wagner, O. F., de Vries, C., Hohmann, C., Veerman, H., and Pannekoek, H. (1989). Interaction between plasminogen activator inhibitor type 1 (PAI- 1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA. J. Clin. Invest. 84, 647-655. doi: 10.1172/jci114211
104. Wang, X., Lee, S. R., Arai, K., Tsuji, K., Rebeck, G. W., and Lo, E. H. (2003). Lipoprotein receptor-mediated induction ofmatrixmetalloproteinase bytissue plasminogen activator. Nat. Med. 9, 1313-1317. doi: 10.1038/nm926
105. Xu, G., Zhang, H., Zhang, S., Fan, X., and Liu, X. (2008). Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int. J. Clin. Pract. 62, 1070-1075. doi: 10.1111/j.1742-1241.2007.01268.x
106. Yang, Y., Tian, S. J., Wu, L., Huang, D. H., and Wu, W. P. (2011). Fibrinogen depleting agent batroxobin has a beneficial effect on experimental autoimmune encephalomyelitis. Cell. Mol. Neurobiol. 31, 437-448. doi: 10.1007/s10571-010-9637-2
107. Yepes, M., Sandkvist, M., Moore, E. G., Bugge, T. H., Strickland, D. K., and Lawrence, D. A. (2003). Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J. Clin. Invest. 112, 1533-1540. doi: 10.1172/jci19212
108. Zamolodchikov, D., Chen, Z. L., Conti, B. A., Renné, T., and Strickland, S. (2015). Activation of the factor XII-driven contact system in Alzheimer’s disease patient and mouse model plasma. Proc. Natl. Acad. Sci. USA 112, 4068-4073. doi: 10.1073/pnas.1423764112
109. Zamolodchikov, D., and Strickland, S. (2012). Abeta delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin. Blood 119, 3342-3351. doi: 10.1182/blood-2011-11-389668
110. Zlokovic, B. V. (2008). The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 57, 178-201. doi: 10.1016/j.neuron.2008.01.003